TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
Hyperphosphorylated transactive response DNA-binding protein 43 (TDP-43, encoded by TARDBP ) proteinopathy has recently been described in ageing and in association with cognitive impairment, especially in the context of Alzheimer's disease pathology. To explore the role of mixed Alzheimer's disease and TDP-43 pathologies in clinical Alzheimer's-type dementia, we performed a comprehensive investigation of TDP-43, mixed pathologies, and clinical Alzheimer's-type dementia in a large cohort of community-dwelling older subjects. We tested the hypotheses that TDP-43 with Alzheimer's disease pathology is a common mixed pathology; is related to increased likelihood of expressing clinical Alzheimer's-type dementia; and that TDP-43 pathologic stage is an important determinant of clinical Alzheimer's-type dementia. Data came from 946 older adults with ( n = 398) and without dementia ( n = 548) from the Rush Memory and Aging Project and Religious Orders Study. TDP-43 proteinopathy (cytoplasmic inclusions) was present in 496 (52%) subjects, and the pattern of deposition was classified as stage 0 (none; 48%), stage 1 (amygdala; 18%), stage 2 (extension to hippocampus/entorhinal; 21%), or stage 3 (extension to neocortex; 14%). TDP-43 pathology combined with a pathologic diagnosis of Alzheimer's disease was a common mixed pathology (37% of all participants), and the proportion of subjects with clinical Alzheimer's-type dementia formerly labelled 'pure pathologic diagnosis of Alzheimer's disease' was halved when TDP-43 was considered. In logistic regression models adjusted for age, sex, and education, TDP-43 pathology was associated with clinical Alzheimer's-type dementia (odds ratio = 1.51, 95% confidence interval = 1.11, 2.05) independent of pathological Alzheimer's disease (odds ratio = 4.30, 95% confidence interval = 3.08, 6.01) or other pathologies (infarcts, arteriolosclerosis, Lewy bodies, and hippocampal sclerosis). Mixed Alzheimer's disease and TDP-43 pathologies were associated with higher odds of clinical Alzheimer's-type dementia (odds ratio = 6.73, 95% confidence interval = 4.18, 10.85) than pathologic Alzheimer's disease alone (odds ratio = 4.62, 95% confidence interval = 2.84, 7.52). In models examining TDP-43 stage, a dose-response relationship with clinical Alzheimer's-type dementia was observed, and a significant association was observed starting at stage 2, extension beyond the amygdala. In this large sample from almost 1000 community participants, we observed that TDP-43 proteinopathy was very common, frequently mixed with pathological Alzheimer's disease, and associated with a higher likelihood of the clinical expression of clinical Alzheimer's-type dementia but only when extended beyond the amygdala.
Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Internal Medicine, 600 s. Paulina Street, Chicago, IL 60612, USA.
Bryan D
BD
James
Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Neurological Sciences, 600 s. Paulina Street, Chicago, IL 60612, USA.|Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Behavioral Sciences, 600 s. Paulina Street, Chicago, IL 60612, USA.
Robert S
RS
Wilson
Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Behavioral Sciences, 600 s. Paulina Street, Chicago, IL 60612, USA.
Patricia A
PA
Boyle
Department of Pathology and Laboratory Medicine, Institute on Aging Center for Neurodegenerative Disease Research, University of Pennsylvania, 3600 Spruce Street, 3rd Floor Maloney Building, Philadelphia, PA 19104-4283, USA.
John Q
JQ
Trojanowski
Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Neurological Sciences, 600 s. Paulina Street, Chicago, IL 60612, USA.
David A
DA
Bennett
Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Neurological Sciences, 600 s. Paulina Street, Chicago, IL 60612, USA.|Rush Alzheimer's Disease Center, Rush University Medical Center, Department of Pathology, 600 s. Paulina Street, Chicago, IL 60612, USA.
Julie A
JA
Schneider
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D050379:Arteriolosclerosis / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D001344:Autopsy; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D020520:Brain Infarction / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D015331:Cohort Studies; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D057187:Independent Living; D008297:Male; D011569:Psychiatric Status Rating Scales; D057177:TDP-43 Proteinopathies / Q000473:pathology*
D004268:DNA-Binding Proteins; C000598624:TARDBP protein, human
Alzheimer’s disease; TDP-43; dementia; epidemiology; neuropathology
Neurology. 2004 Apr 13;62(7):1148-55
15079015
Stroke. 2011 Mar;42(3):722-7
21212395
J Alzheimers Dis. 2009;18(3):691-701
19749406
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2
9330978
Neurology. 2006 Mar 14;66(5):775
16534130
Ann Neurol. 2007 May;61(5):435-45
17469117
Acta Neuropathol. 2016 Apr;131(4):571-85
26810071
Stroke. 2011 Nov;42(11):3183-9
21885844
Ann Neurol. 2015 Jun;77(6):942-52
25707479
Psychol Aging. 2002 Jun;17(2):179-93
12061405
Brain Res. 2007 Dec 12;1184:284-94
17963732
Brain. 2011 Dec;134(Pt 12):3708-15
22120149
J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64
18520774
J Neuropathol Exp Neurol. 2011 Sep;70(9):788-98
21865887
Int J Clin Exp Pathol. 2011 Jan 30;4(2):147-55
21326809
Acta Neuropathol. 2013 Jul;126(1):51-7
23604587
Brain Behav. 2012 Jul;2(4):435-42
22950047
J Neural Transm (Vienna). 2011 May;118(5):683-9
21210283
J Alzheimers Dis. 2014;42(2):641-50
25170584
Science. 2006 Oct 6;314(5796):130-3
17023659
Acta Neuropathol. 1991;82(4):239-59
1759558
Neurology. 2015 Mar 3;84(9):927-34
25653292
Ann Neurol. 2009 Aug;66(2):200-8
19743450
Acta Neuropathol. 2011 Dec;122(6):703-13
21968532
Neurology. 2008 May 6;70(19 Pt 2):1850-7
18401022
Acta Neuropathol. 2009 Feb;117(2):125-36
19139911
Curr Alzheimer Res. 2012 Jul;9(6):646-63
22471867
Neuroepidemiology. 2005;25(4):163-75
16103727
J Int Neuropsychol Soc. 2005 Jul;11(4):400-7
16209420
Acta Neuropathol. 2014;127(6):811-24
24659241
Neurology. 2007 Dec 11;69(24):2197-204
17568013
JAMA Neurol. 2013 Nov;70(11):1418-24
24080705
Ann Neurol. 2013 Sep;74(3):478-89
23798485
Acta Neuropathol. 2009 Feb;117(2):137-49
19125255
Neurology. 1991 Apr;41(4):479-86
2011243
Exp Neurol. 2012 Sep;237(1):90-5
22691390
Prog Neurobiol. 2011 Dec;95(4):649-62
21911035
Neurology. 2006 Jun 27;66(12):1837-44
16801647
Acta Neuropathol. 2014 Mar;127(3):441-50
24240737
Arch Neurol. 2010 Oct;67(10):1238-50
20937952
Neurology. 2002 Jul 23;59(2):198-205
12136057
J Neural Transm (Vienna). 2015 Apr;122(4):505-21
25091618
Neurology. 2015 Mar 3;84(9):870-1
25653288
Acta Neuropathol. 2010 Jul;120(1):43-54
20361198
Curr Alzheimer Res. 2012 Jul;9(6):628-45
22471860
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
17084815
J Alzheimers Dis. 2013;33 Suppl 1:S397-403
22647261
Mol Neurobiol. 2016 Jul;53(5):3349-59
26081142
Brain. 2011 May;134(Pt 5):1506-18
21596774
Brain Pathol. 2010 Jan;20(1):66-79
19021630
Brain Pathol. 2017 Jan;27(1):77-85
26844934
Acta Neuropathol. 2008 Aug;116(2):215-20
18592255
Neurology. 1984 Jul;34(7):939-44
6610841
Neurology. 2005 Dec 27;65(12):1863-72
16237129
J Neuropathol Exp Neurol. 2016 May;75(5):397-407
26971127
Neuroepidemiology. 2006;27(3):169-76
17035694
Neuropathology. 2009 Oct;29(5):566-73
19422539